Earnings Labs

Xtant Medical Holdings, Inc. (XTNT)

Q2 2020 Earnings Call· Mon, Aug 3, 2020

$0.56

+6.64%

Key Takeaways · AI generated
AI summary not yet generated for this transcript. Generation in progress for older transcripts; check back soon, or browse the full transcript below.

Same-Day

-13.33%

1 Week

+22.50%

1 Month

-27.74%

vs S&P

-36.53%

Transcript

Operator

Operator

Greetings and welcome to Xtant Medical second quarter 2020 financial results conference call. At this time, all participants are in a listen-only mode. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to turn the conference over to Matt Steinberg of Lazar FINN Partners. Please go ahead.

Matt Steinberg

Analyst

Thank you operator and welcome to Xtant Medical's second quarter 2020 financial results call. Joining me today is Sean Browne, President and Chief Executive Officer and Greg Jensen, Vice President of Finance and Chief Financial Officer. Today's call is being webcast and will be posted on the company's website for playback. During the course of this call, management may make certain forward-looking statements regarding future events and the company's expected future performance. These forward-looking statements reflect Xtant's current perspective on existing trends and information and can be identified by such words as expect, plan, will, may, anticipate, believe, should, intends and other words with similar meaning. Any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties including those noted in the Risk Factors section of the company's Annual Report on Form 10-K filed with the SEC on March 5, 2020 and as supplemented by the company's subsequent SEC filings. Actual results may differ materially. The company's financial results, press release and today's discussion include certain non-GAAP financial measures. Please refer to the non-GAAP to GAAP reconciliations which appear in the tables of our press release and are otherwise available on our website. Note that our Form 8-K filed with our financial results press release provides a detailed narrative that describes our use of such measures. For the benefit of those of you who may be listening to the replay, this call was held and recorded on Monday, August third at approximately 4:30 P.M. Eastern Daylight Time. The company declines any obligation to update its forward-looking statements, except as required by applicable law. Now, I would like to turn the call over to Sean Browne.

Sean Browne

Analyst

Thank you Matt and good afternoon to everyone listening. The second quarter of 2020 was truly an unprecedented and unique time, not only in our company's history but also in the healthcare sector and global economy. At the start of the quarter, the pandemic outbreak surged across the country creating restrictions on elective procedures that put the majority of spinal procedures on hold. Throughout the second quarter, we saw a dramatic uptick in the month-to-month spinal elective procedures. And supported by pent-up demand, we generated revenues of $10.5 million in the second quarter. The spine market tends to be the least elective of elective procedures since patients are in such still debilitating pain and as such these procedures were among the first to resume. Beginning in March at the start of the pandemic, we implemented a series of strategic actions to adapt to the new environment and maintain business continuity while positioning the company to emerge from the pandemic in a position of strength. As we previously announced in the first quarter, we focused on four areas to achieve those objectives and our results in the second quarter reflect early positive returns. First and foremost, we focused on and we continue to prioritize keeping our employees and their families safe and healthy through social distancing and work from home procedures where possible. Second, to conserve our cash, we initiated extensive cost reductions at the end of the first quarter. This included significant workforce reductions and across-the-board pay decrease for all employees as well as our Board of Directors. In addition, we enacted deep cuts in discretionary spending and capital expenditures. These swift actions to reduce expenses enabled us to conserve cash and rightsize our cost structure during this uncertain environment. Going forward, we will improvement in our expense management as…

Greg Jensen

Analyst

Thanks Sean and good afternoon everyone. Total revenue for the second quarter of 2020 was $10.5 million compared to $15.3 million for the same period in 2019. For the first half of 2020, total revenue was $25.3 million compared to $32 million for the first half of 2019. These decreases are attributed to the impact of COVID-19 and the sudden drop in elective procedures beginning in early March. As Sean mentioned earlier, sales gradually improved throughout the second quarter driven by a resumption of elective procedures. Gross margin for the second quarter of 2020 was 62.2% compared to 64.9% for the same period in 2019. Gross margin for the first half of 2020 was 63.9% compared to 64.8% for the first half of 2019. The decrease in gross margin as a percentage of sales is attributed to the decrease in second quarter sales. Second quarter 2020 operating expenses were $6.9 million compared to $10.5 million in the same period a year ago. For the first six months of 2020, operating expenses were $17.9 million compared to $22 million in 2019. As a percentage of total revenue, operating expenses were 65.9% and 70.8% for the three and six months ended June 30, 2020, respectively, compared to 68.6% for both the three and six month periods ended June 30, 2019. General and administrative expenses decreased by $1.3 million to $2.9 million for the three months ended June 30, 2020 compared to the same period in 2019 and decreased by $1.4 million to $7.3 million for the first half of 2020 compared to the same period in 2019. These decreases were primarily due to a reduction in salary and wages, lower legal and consulting fees and reduced legal settlement expenses, partially offset by additional stock-based compensation expense and severance-related expenses from the workforce…

Sean Browne

Analyst

Thank you Greg. In closing, against a difficult direct backdrop facing the healthcare industry entering the second quarter, the month-by-month uptick in spinal elective procedures combined with pent-up demand enabled us to deliver a solid revenue performance, that only months earlier was far bleaker. Unfortunately, the pandemic continues to create regional uncertainties, especially in areas of the country where we are strongest. We will remain vigilant on managing our expenses and improving operations so that we can adapt our business to the new environment. I look forward to providing updates on our progress on future calls. Wish all those listening on today's call, good health. Thank you for your continued support. End of Q&A: This concludes today's conference. Thank you for your participation. You may disconnect your lines at this time.